Central Nervous System Lymphoma
Oncology
3
Pipeline Programs
3
Companies
3
Clinical Trials
2 recruiting
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
2
0
0
0
0
Early DiscoveryClinical DevelopmentMarket
Drug Modality Breakdown
Monoclonal Antibody
1100%
+ 2 programs with unclassified modality
Competitive Landscape
3 companies ranked by most advanced pipeline stage
ADC TherapeuticsNJ - New Providence
1 program1
Loncastuximab tesirine and rituximabPhase 1Monoclonal Antibody1 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
AntengeneSelinexor
Knight TherapeuticsCarboplatin
ADC TherapeuticsLoncastuximab tesirine and rituximab
Clinical Trials (3)
Total enrollment: 81 patients across 3 trials
Selinexor in Combination With MTX+Ritu to Treat R/R CNSL
Start: Aug 2023Est. completion: Dec 2026
Phase 1/2Recruiting
Methotrexate, Mannitol, Rituximab, and Carboplatin in Treating Patients With Newly Diagnosed Primary Central Nervous System Lymphoma
Start: Oct 2005Est. completion: Jan 202381 patients
Phase 1/2Unknown
Loncastuximab Tesirine and Rituximab Following Stereotactic Radiosurgery in Patients With Central Nervous System Lymphomas (SOLAR)
Start: Mar 2025Est. completion: Nov 2030
Phase 1Recruiting
Related Jobs in Oncology
Cell Therapy Account Manager（北陸）
Gilead Sciences
Japan - Tokyo
Just now
Leo Cancer Care: Senior In-House Counsel/General Counsel
Leo Cancer Care
Middleton, Wisconsin
5h ago
Summer Intern - Computational Chemistry & Artificial Intelligence
Arvinas
Remote
7h ago
Executive Medical Director, Oncology Early Development
AbbVie
Florham Park, NJ
8h ago
Executive Medical Director, Oncology Early Development
AbbVie
South San Francisco, CA
8h ago
Executive Medical Director, Oncology Early Development
AbbVie
North Chicago, IL
8h ago
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
2 actively recruiting trials targeting 81 patients
3 companies competing in this space